The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Clinical and molecular presentation of KRAS G12D-mutated pancreatic ductal adenocarcinoma in real-world settings.
 
Emma G. Sturgill
Employment - HCA/Sarah Cannon
Stock and Other Ownership Interests - HCA Healthcare
 
Sahiti Kolli
Employment - HCA/Sarah Cannon
 
Kavanya Feustel
No Relationships to Disclose
 
Daniel Luckett
Employment - HCA/Sarah Cannon
Stock and Other Ownership Interests - HCA/Sarah Cannon
 
Carissa Jones
Employment - HCA/Sarah Cannon
 
Marilyn Elaine Holt
Employment - HCA/Sarah Cannon
Research Funding - GenomOncology (Inst)
 
Annastasia Hyde
Employment - Sarah Cannon Research Institute
Stock and Other Ownership Interests - HCA/Sarah Cannon
 
Suzanne Fields Jones
Employment - HCA/Sarah Cannon
Stock and Other Ownership Interests - HCA Healthcare
Consulting or Advisory Role - Amgen (Inst)
 
Cesar Augusto Perez
Research Funding - Accutar Biotech (Inst); Alkermes (Inst); Artios (Inst); Ayala Pharmaceuticals (Inst); Elpiscience (Inst); Hyamab (Inst); Kinnate Biopharma (Inst); Kura Oncology (Inst); Mirati Therapeutics (Inst); Pfizer (Inst); Relay Therapeutics (Inst); Ribon Therapeutics (Inst); Seagen (Inst); Tallac Therapeutics (Inst); Xilio Therapeutics (Inst)
 
Judy S. Wang
Consulting or Advisory Role - BioNTech; Janssen Research & Development; Kanaph Therapeutics; Stemline Therapeutics
Speakers' Bureau - AstraZeneca; Eisai
Research Funding - Adagene (Inst); Agenus (Inst); Artios (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer Health (Inst); BeiGene (Inst); Bicycle Therapeutics (Inst); BioNTech (Inst); Biosplice (Inst); BioTheryX (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Celgene (Inst); CicloMed (Inst); Clovis Oncology (Inst); Cullinan Oncology (Inst); cyteir (Inst); Daiichi Sankyo (Inst); Erasca, Inc (Inst); Forty Seven (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); H3 Biomedicine (Inst); Hutchison MediPharma (Inst); IgM Biosciences (Inst); Immune-Onc Therapeutics (Inst); Immunogen (Inst); Jacobio (Inst); Janssen Research & Development (Inst); Jazz Pharmaceuticals (Inst); Klus Pharma (Inst); Kymab (Inst); Loxo (Inst); LSK BioPharma (Inst); MabSpace Biosciences (Inst); Macrogenics (Inst); Merck (Inst); Metabomed (Inst); Moderna Therapeutics (Inst); NGM Biopharmaceuticals (Inst); Novartis (Inst); Nurix (Inst); Olema Oncology (Inst); ORIC Pharmaceuticals (Inst); Phoenix Pharmaceuticals (Inst); Prelude Therapeutics (Inst); PureTech (Inst); QiLu Pharmaceutical (Inst); Relay Therapeutics (Inst); Revolution Medicines (Inst); Ribon Therapeutics (Inst); Seven and Eight Biopharmaceuticals (Inst); Stemline Therapeutics (Inst); Syndax (Inst); Taiho Pharmaceutical (Inst); TeneoBio (Inst); Tesaro (Inst); TopAlliance BioSciences Inc (Inst); Treadwell Therapeutics (Inst); Xencor (Inst); Zymeworks (Inst)
 
Stephen G. Divers
No Relationships to Disclose
 
Meredith Pelster
Honoraria - Castle Biosciences (I)
Consulting or Advisory Role - AstraZeneca (Inst); Bayer (Inst); Novartis (Inst); Pfizer (Inst); Seagen (Inst)
Research Funding - Arcus Biosciences (Inst); Astellas Pharma (Inst); Codiak Biosciences (Inst); CytomX Therapeutics (Inst); Eisai (Inst); Gritstone Bio (Inst); HiberCell (Inst); Immune-Onc Therapeutics (Inst); OncXerna Therapeutics (Inst); SQZ Biotechnology (Inst); Surface Oncology (Inst); TransThera Sciences (Nanjing), Inc. (Inst); ZielBio (Inst)
 
Jason Timothy Henry
Research Funding - Abbisko (Inst); ABL Bio (Inst); accutar biotech (Inst); ADC Therapeutics (Inst); Aileron Therapeutics (Inst); Amgen (Inst); Artios (Inst); AstraZeneca/Merck (Inst); Bicycle Therapeutics (Inst); BioAtla (Inst); Bioinvent (Inst); Biosplice (Inst); Boehringer Ingelheim (Inst); cyteir (Inst); DaiichI Sankyo (Inst); Epizyme (Inst); Erasca, Inc (Inst); Exelixis (Inst); Fujifilm (Inst); GlaxoSmithKline (Inst); Hutchison MediPharma (Inst); IgM Biosciences (Inst); Immunogen (Inst); Jacobio (Inst); Jounce Therapeutics (Inst); Lilly (Inst); Loxo (Inst); Merck (Inst); Molecular Templates (Inst); Navire (Inst); NiKang Therapeutics (Inst); Oncorus (Inst); Poseida therapeutics (Inst); Prelude Therapeutics (Inst); PureTech (Inst); Pyramid Biosciences (Inst); RasCal (Inst); Regeneron (Inst); Relay Therapeutics (Inst); Rgenix (Inst); Ribon Therapeutics (Inst); Sapience Therapeutics (Inst); Sarah Cannon Research Institute (Inst); Sarah Cannon Research Institute (Inst); Simcha Therapeutics (Inst); Sirnaomics (Inst); Stingthera (Inst); Synthorx (Inst); Takeda (Inst); Tarveda Therapeutics (Inst); Teneothree (Inst); Tesaro (Inst); Turning Point Therapeutics (Inst); Xencor (Inst)
 
David R. Spigel
Leadership - ASCO (Inst)
Consulting or Advisory Role - Amgen (Inst); AstraZeneca (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Curio Science (Inst); EMD Serono (Inst); Evidera (Inst); Exelixis (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Intellisphere (Inst); Janssen (Inst); Jazz Pharmaceuticals (Inst); Lilly (Inst); Mirati Therapeutics (Inst); Molecular Templates (Inst); Novartis (Inst); Novocure (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Regeneron (Inst); Sanofi/Aventis (Inst)
Research Funding - Aeglea Biotherapeutics (Inst); Agios (Inst); Apollomics (Inst); Arcus Biosciences (Inst); Arrys Therapeutics (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); BIND Therapeutics (Inst); BioNTech (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celgene (Inst); Celldex (Inst); Clovis Oncology (Inst); cyteir (Inst); Daiichi Sankyo (Inst); Denovo Biopharma (Inst); Eisai (Inst); Elevation Oncology (Inst); EMD Serono (Inst); Evelo Biosciences (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); GRAIL (Inst); Hutchison MediPharma (Inst); ImClone Systems (Inst); Immunogen (Inst); Incyte (Inst); Ipsen (Inst); Janssen Oncology (Inst); Kronos Bio (Inst); Lilly (Inst); Loxo (Inst); Macrogenics (Inst); MedImmune (Inst); Merck (Inst); Molecular Partners (Inst); Molecular Templates (Inst); Nektar (Inst); Neon Therapeutics (Inst); Novartis (Inst); Novocure (Inst); Oncologie (Inst); Pfizer (Inst); PTC Therapeutics (Inst); PureTech (Inst); Razor Genomics (Inst); Repare Therapeutics (Inst); Rgenix (Inst); Takeda (Inst); Tesaro (Inst); Tizona Therapeutics, Inc. (Inst); Transgene (Inst); University of Texas Southwestern Medical Center - Simmons Cancer Center (Inst); Verastem (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Genentech; Novartis
 
Howard A. Burris III
Employment - HCA Healthcare
Leadership - HCA Healthcare
Stock and Other Ownership Interests - HCA Healthcare
Research Funding - Abbvie (Inst); Agios (Inst); Archer (Inst); ARMO BioSciences (Inst); Array BioPharma (Inst); Arvinas (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); BioAtla (Inst); BioMed Valley Discoveries (Inst); BioTheryX (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); CALGB (Inst); CicloMed (Inst); Coordination Pharmaceuticals (Inst); CytomX Therapeutics (Inst); eFFECTOR Therapeutics (Inst); EMD Serono (Inst); Foundation Medicine (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Gossamer Bio (Inst); Harpoon therapeutics (Inst); Hengrui Therapeutics (Inst); Incyte (Inst); Janssen (Inst); Jounce Therapeutics (Inst); Kymab (Inst); Lilly (Inst); Macrogenics (Inst); MedImmune (Inst); Merck (Inst); Moderna Therapeutics (Inst); NGM Biopharmaceuticals (Inst); Novartis (Inst); Pfizer (Inst); Revolution Medicines (Inst); Roche/Genentech (Inst); Ryvu Therapeutics (Inst); Seagen (Inst); Takeda/Millennium (Inst); Tesaro (Inst); TG Therapeutics (Inst); Verastem (Inst); Vertex (Inst); XBiotech (Inst); Zymeworks (Inst)
(OPTIONAL) Uncompensated Relationships - AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); GRAIL (Inst); Incyte (Inst); Novartis (Inst); TG Therapeutics (Inst); Vincerx Pharma (Inst)
 
Andrew Jacob McKenzie
Employment - HCA Healthcare
Stock and Other Ownership Interests - HCA Healthcare